HUE032867T2 - New patient group for thrombolysis - Google Patents

New patient group for thrombolysis Download PDF

Info

Publication number
HUE032867T2
HUE032867T2 HUE08838897A HUE08838897A HUE032867T2 HU E032867 T2 HUE032867 T2 HU E032867T2 HU E08838897 A HUE08838897 A HU E08838897A HU E08838897 A HUE08838897 A HU E08838897A HU E032867 T2 HUE032867 T2 HU E032867T2
Authority
HU
Hungary
Prior art keywords
stroke
patient
desmoteplase
patients
occlusion
Prior art date
Application number
HUE08838897A
Other languages
English (en)
Hungarian (hu)
Inventor
Mariola Soehngen
Alice Ebel
Yasir Alaa Shafeek Al-Rawi
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40567844&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE032867(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from EP07020401A external-priority patent/EP2050462A1/en
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of HUE032867T2 publication Critical patent/HUE032867T2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Electrotherapy Devices (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
HUE08838897A 2007-10-18 2008-10-20 New patient group for thrombolysis HUE032867T2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07020401A EP2050462A1 (en) 2007-10-18 2007-10-18 Improved treatment of stroke patients
EP07022867 2007-11-26
EP08017954 2008-10-15

Publications (1)

Publication Number Publication Date
HUE032867T2 true HUE032867T2 (en) 2017-11-28

Family

ID=40567844

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE08838897A HUE032867T2 (en) 2007-10-18 2008-10-20 New patient group for thrombolysis

Country Status (28)

Country Link
US (2) US20100272704A1 (enExample)
EP (1) EP2211898B1 (enExample)
JP (2) JP5509085B2 (enExample)
KR (1) KR20100089077A (enExample)
CN (1) CN101903039B (enExample)
AR (1) AR068914A1 (enExample)
AU (1) AU2008314048B2 (enExample)
BR (1) BRPI0817785A2 (enExample)
CA (1) CA2702378A1 (enExample)
CL (1) CL2009000752A1 (enExample)
CY (1) CY1118417T1 (enExample)
DK (1) DK2211898T3 (enExample)
EA (1) EA020776B1 (enExample)
ES (1) ES2611155T3 (enExample)
HR (1) HRP20170001T1 (enExample)
HU (1) HUE032867T2 (enExample)
IL (1) IL205175A0 (enExample)
LT (1) LT2211898T (enExample)
MX (1) MX2010004157A (enExample)
MY (1) MY159200A (enExample)
NZ (1) NZ584640A (enExample)
PL (1) PL2211898T3 (enExample)
PT (1) PT2211898T (enExample)
RS (1) RS55590B1 (enExample)
SI (1) SI2211898T1 (enExample)
TW (1) TWI482628B (enExample)
WO (1) WO2009049914A2 (enExample)
ZA (1) ZA201002548B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10153601A1 (de) 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766075A (en) * 1982-07-14 1988-08-23 Genentech, Inc. Human tissue plasminogen activator
US5244806A (en) * 1985-08-26 1993-09-14 Eli Lilly And Company DNA encoding novel tissue plasminogen activator derivatives having kringles 1 and 2 deleted, vectors and host cells
IL87276A (en) * 1987-08-03 1995-07-31 Fujisawa Pharmaceutical Co Analog of tissue plasminogen activator comprising only the kringle 2 and protease domain dna encoding the same processes for the preparation thereof and pharmaceutical compositions containing the same
US5094953A (en) * 1988-03-21 1992-03-10 Genentech, Inc. Human tissue plasminogen activator variants
FI100403B (fi) * 1988-07-20 1997-11-28 Schering Ag Menetelmä glykosyloitujen tai glykosyloimattomien vampyyrilepakon sylj en plasminogeeniaktivaattoreiden valmistamiseksi
US5714145A (en) * 1988-09-02 1998-02-03 Genentech, Inc. Tissue plasminogen activator having zymogenic or fibrin specific properties
US5676947A (en) * 1989-02-07 1997-10-14 Boehringer Manneheim Gmbh Method for treating thromboembolic conditions using thrombolytically active proteins
DE3903581A1 (de) * 1989-02-07 1990-08-16 Boehringer Mannheim Gmbh Gewebs-plasminogenaktivator-derivat
US6008019A (en) * 1989-02-13 1999-12-28 Schering Aktiengesellschaft Plasminogen activator from saliva of the vampire bat
US5891664A (en) * 1989-04-07 1999-04-06 Cancerforskningsfondet Af 1989 Vectors and methods for recombinant production of uPA-binding fragments of the human urokinase-type plasminogen receptor (uPAR)
US5326700A (en) * 1990-11-06 1994-07-05 Eli Lilly And Company DNA sequences encoding t-PA derivatives with cleavable sites
DK0580685T3 (da) * 1991-04-16 1996-03-04 Boehringer Mannheim Gmbh Farmaceutisk emballageenhed indeholdende plasminogenaktivatorer til flerfoldig bolusindgift
US5595736A (en) * 1991-04-22 1997-01-21 Eli Lilly And Company Compounds and methods for treatment of thromboembolic disorders
RU2183214C2 (ru) * 1992-12-04 2002-06-10 Шеринг Аг Природный и рекомбинантный ингибиторы тромбина, их получение и применение
US5510330A (en) * 1994-03-25 1996-04-23 Boehringer Mannheim Gmbh Combinations of thrombolytically active proteins and non-heparin anticoagulants, and uses thereof.
GB9412131D0 (en) * 1994-06-17 1994-08-10 British Bio Technology Thrombolytic composition
US5827832A (en) * 1995-03-06 1998-10-27 Interneuron Pharmaceuticals, Inc. Method of protecting brain tissue from cerebral infarction subsequent to ischemia
US5786187A (en) * 1995-09-21 1998-07-28 The Research Foundation Of State University Of New York Method for reducing neuronal degeneration associated with seizure
US5945432A (en) * 1995-12-22 1999-08-31 The University Of Vermont And State Agricultural College Thrombolytic agents and thienopyridine derivatives in acute stroke
US20020081294A1 (en) * 1996-01-23 2002-06-27 Genentech, Inc. Co-administration of a thrombolytic and an anti-CD18 antibody in stroke
US5731186A (en) * 1996-02-05 1998-03-24 Schering Aktiengesellschaft Method for the production of rDSPA α1
US6354999B1 (en) * 2000-01-14 2002-03-12 Florence Medical Ltd. System and method for detecting, localizing, and characterizing occlusions and aneurysms in a vessel
GB0025473D0 (en) * 2000-10-17 2000-11-29 Pfizer Ltd Pharmaceutical combinations
DE10153601A1 (de) * 2001-11-02 2003-05-22 Paion Gmbh DSPA zur Behandlung von Schlaganfall
US20060135425A1 (en) * 2003-05-02 2006-06-22 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
US20080057050A1 (en) * 2003-05-02 2008-03-06 Paion Deutschland Gmbh Intravenous injection of plasminogen non-neurotoxic activators for treating cerebral stroke
KR20060015721A (ko) * 2003-05-05 2006-02-20 파이온 도이치란트 게엠베하 신경보호제로서의 글루타메이트 수용체 길항제
US20050085478A1 (en) * 2003-08-22 2005-04-21 Pharmacia Corporation Compositions of a cyclooxygenase-2 selective inhibitor and a low-molecular-weight heparin for the treatment of central nervous system damage
WO2007025219A2 (en) * 2005-08-25 2007-03-01 Biogen Idec Ma Inc. Nogo receptor polypeptides and polypeptide fragments and uses thereof

Also Published As

Publication number Publication date
CL2009000752A1 (es) 2009-12-04
HK1151233A1 (en) 2012-01-27
RS55590B1 (sr) 2017-06-30
JP2014065739A (ja) 2014-04-17
US20140314736A1 (en) 2014-10-23
AU2008314048B2 (en) 2013-07-25
CA2702378A1 (en) 2009-04-23
MX2010004157A (es) 2010-04-30
JP5509085B2 (ja) 2014-06-04
EA201070485A1 (ru) 2010-10-29
AU2008314048A1 (en) 2009-04-23
EA020776B1 (ru) 2015-01-30
ES2611155T3 (es) 2017-05-05
JP2011500617A (ja) 2011-01-06
TWI482628B (zh) 2015-05-01
KR20100089077A (ko) 2010-08-11
HRP20170001T1 (hr) 2017-02-24
PL2211898T3 (pl) 2017-03-31
SI2211898T1 (sl) 2017-02-28
ZA201002548B (en) 2011-06-29
CN101903039A (zh) 2010-12-01
MY159200A (en) 2016-12-30
LT2211898T (lt) 2017-01-25
DK2211898T3 (en) 2017-01-30
WO2009049914A2 (en) 2009-04-23
AR068914A1 (es) 2009-12-16
EP2211898B1 (en) 2016-12-07
BRPI0817785A2 (pt) 2015-03-24
NZ584640A (en) 2012-10-26
WO2009049914A3 (en) 2009-08-06
CY1118417T1 (el) 2017-06-28
IL205175A0 (en) 2010-11-30
PT2211898T (pt) 2017-01-31
US20100272704A1 (en) 2010-10-28
TW200927164A (en) 2009-07-01
EP2211898A2 (en) 2010-08-04
CN101903039B (zh) 2014-04-02

Similar Documents

Publication Publication Date Title
Xiong et al. Tenecteplase for ischemic stroke at 4.5 to 24 hours without thrombectomy
Von Kummer et al. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke.
Wu et al. Assessing the clinical efficacy of recombinant tissue plasminogen activator on acute cerebral infarction
EP2050462A1 (en) Improved treatment of stroke patients
Kim et al. Rescue localized intra-arterial thrombolysis for hyperacute MCA ischemic stroke patients after early non-responsive intravenous tissue plasminogen activator therapy
EP2211898B1 (en) Novel patient subgroups for thrombolysis
Zhu et al. Safety and efficacy of intravenous Tirofiban infusion after mechanical thrombectomy in acute ischemic stroke: a retrospective observational study
JP2011500617A5 (enExample)
Huang et al. Efficacy of intravenous thrombolysis combined with mechanical stent interventional thrombectomy on acute ischemic stroke
HK1151233B (en) Novel patient subgroups for thrombolysis
Wang et al. The comparative study on therapeutic effects of intravenous alteplase thrombolysis, intravenous urokinase thrombolysis and interventional urokinase thrombolysis for acute ischemic stroke
Sun et al. Effects of alteplase and aspirin on functional outcomes in patients with acute ischemic stroke and mild non-disabling neurological deficit
Zhang et al. Efficacy and safety of intracoronary thrombolysis versus PCI in myocardial infarction patients
Kaste et al. The European cooperative acute stroke study (ECASS)
Machraoui et al. Efficacy and safety of APSAC in the treatment of acute myocardial infarction
Cai¹ et al. Stroke: Rationale, Design and Protocol for a Prospective
Oguro et al. Effect of one-shot intravenous 0.42 mega unit urokinase therapy in patients with acute ischemic stroke
Venketasubramanian et al. Brain attack: needing resuscitation
Shi et al. Effect and safety of arterial thrombolysis added to solitaire AB stents interventional treatment in acute ischemic stroke
Goldstein Medical therapy for acute ischemic stroke
Petrov et al. Iveta Tasheva, et al. Single Center Experience with Catheter Based Treatment in Acute Ischemic Stroke
Emde et al. Current practices with thrombolytic therapy
Wong et al. Acute ischaemic stroke: management, recent advances and controversies
Schellinger Stroke management in the early phase
Csiba et al. Fibrin-degrading drugs in acute stroke